| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2863760 | The American Journal of the Medical Sciences | 2014 | 6 Pages |
Abstract
Administration of spironolactone reduced the composite of death and cardiovascular hospitalization in patients with NYHA classes I to II HF. These results suggest that spironolactone could be beneficial when administered on top of optimal therapy among patients with HF and mild or no symptoms.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Enrico MD, Savina MD, Giorgio MD, Antonio MD, Natalia MD, Giacomo MD, Carlo MD, Riccardo MD, Marco MD, Livio Dei MD,